KTM
NVO

Keeler Thomas Management’s Novo Nordisk NVO Stock Holding History

Keeler Thomas Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,138
Closed -$1.12M – 123
2025
Q1 		$1.12M Sell
16,138
-3,889
-19% -$321K 0.55% 56
2024
Q4 		$1.72M Sell
20,027
-45
-0.2% -$4.87K 0.61% 49
2024
Q3 		$2.39M Sell
20,072
-29
-0.1% -$3.87K 0.76% 50
2024
Q2 		$2.87M Sell
20,101
-6,644
-25% -$880K 0.98% 47
2024
Q1 		$3.43M Sell
26,745
-116
-0.4% -$13.8K 1.18% 40
2023
Q4 		$2.78M Sell
26,861
-2,135
-7% -$211K 1.1% 39
2023
Q3 		$2.64M Sell
28,996
-1,342
-4% -$118K 0.98% 36
2023
Q2 		$2.45M Sell
30,338
-1,348
-4% -$110K 0.99% 38
2023
Q1 		$2.52M Sell
31,686
-94,450
-75% -$6.7M 1.19% 28
2022
Q4 		$8.54M Sell
126,136
-1,610
-1% -$94.4K 4.3% 3
2022
Q3 		$6.36M Buy
127,746
+4,112
+3% +$220K 3.23% 10
2022
Q2 		$6.89M Buy
123,634
+1,600
+1% +$88.8K 3.41% 9
2022
Q1 		$6.78M Buy
122,034
+8,526
+8% +$438K 3.25% 10
2021
Q4 		$6.36M Buy
113,508
+3,682
+3% +$199K 2.75% 10
2021
Q3 		$5.28M Buy
109,826
+1,040
+1% +$50.3K 2.51% 11
2021
Q2 		$4.56M Buy
108,786
+3,084
+3% +$120K 2.23% 12
2021
Q1 		$3.57M Buy
105,702
+63,392
+150% +$2.26M 1.88% 25
2020
Q4 		$1.48M Buy
42,310
+15,410
+57% +$533K 0.83% 41
2020
Q3 		$933K Hold
26,900
– – 0.59% 48
2020
Q2 		$880K Sell
26,900
-100
-0.4% -$3.19K 0.64% 46
2020
Q1 		$812K Sell
27,000
-4,100
-13% -$122K 0.95% 37
2019
Q4 		$900K Buy
31,100
+900
+3% +$24.9K 0.64% 41
2019
Q3 		$780K Buy
30,200
+4,400
+17% +$111K 0.6% 45
2019
Q2 		$658K Hold
25,800
– – 0.52% 46
2019
Q1 		$674K Buy
25,800
+4,400
+21% +$108K 0.57% 45
2018
Q4 		$492K Buy
21,400
+6,912
+48% +$154K 0.57% 43
2018
Q3 		$341K Hold
14,488
– – 0.28% 53
2018
Q2 		$334K Buy
14,488
+800
+6% +$19K 0.31% 52
2018
Q1 		$337K Hold
13,688
– – 0.33% 50
2017
Q4 		$367K Buy
+13,688
New +$348K 0.34% 48

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Keeler Thomas Management's NVO Position: Q2 2025 in Review

Keeler Thomas Management sold out of Novo Nordisk (NVO) in Q2 2025, closing a stake of 16,138 shares — an estimated $1.12M sold.

Keeler Thomas Management first reported a position in NVO in Q4 2017 and held it in 30 quarters. The position peaked at $8.54M in Q4 2022. 1,481 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

  • Keeler Thomas Management reported no remaining Novo Nordisk position as of Q2 2025 after selling out during the quarter.
  • Keeler Thomas Management sold 16,138 Novo Nordisk shares in Q2 2025, an estimated $1.12M.
  • Keeler Thomas Management first reported a position in Novo Nordisk in Q4 2017 and held it in 30 quarters.
  • Keeler Thomas Management's Novo Nordisk position peaked at $8.54M in Q4 2022.
  • 1,481 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on Keeler Thomas Management's 13F filing for Q2 2025, filed 31 Jul 2025.